Not Yet Recruiting PHASE2 INTERVENTIONAL 2-arm
NCT07365475
Efficacy and Safety of Intra-Arterial Albumin as Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke (AMASS2)
Efficacy and Safety of Intra-Arterial Albumin as Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke: A Multicenter, Prospective, Open-Label, Endpoint-Blinded, Randomized Controlled Clinical Trial (AMASS2)
Sponsor: Tianjin Huanhu Hospital
Interventions
20% human serum albumin
Updated 1 time since 2026 Last updated: Jan 16, 2026 Started: Jan 30, 2026 Primary completion: Jun 30, 2028 Completion: Aug 30, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE2 clinical study on Acute Ischemic Stroke From Large Vessel Occlusion, this trial is actively recruiting participants. The trial is conducted by Tianjin Huanhu Hospital and has accumulated 1 data snapshot since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Tianjin Huanhu Hospital
Data source: Tianjin Huanhu Hospital
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.